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N E U R O D E G E N E R A T I O N  
Parkin function in Parkinson’s disease 
Models of Parkin-mediated ubiquitination lends insight into the role of pathological mu-
tations 
By Connor Arkinson and Helen Walden 
Parkinson’s disease (PD) is the second most 
common neurodegenerative disease, and is 
characterized by involuntary shaking, muscle ri-
gidity, and the progressive loss of dopaminergic 
neurons. In ~5 to 10% of PD cases there is a ge-
netic association, with almost 20 genes at-
tributed to date. One example is early-onset 
autosomal recessive (AR) PD, for which the ma-
jority of cases are linked to mutations in the 
Parkin gene (PRKN; also known as PARK2). 
PRKN encodes the E3 ubiquitin ligase Parkin, 
which plays important roles in mitochondrial 
quality control and turnover. Parkin, although 
localized to the mitochondria under certain 
conditions, is primarily cytosolic (1). A second 
ARPD-associated gene, PINK1 (PTEN-induced 
putative kinase 1), encodes a mitochondrially 
tethered kinase that regulates Parkin activity 
through phosphorylation events. Mutations in 
PINK1, although rare, are associated with a 
phenotype similar to that of ARPD patients 
with PRKN mutations. Numerous mutations 
throughout PRKN are linked to ARPD, making 
the functional examination of Parkin crucial to 
understanding ARPD pathogenesis. A wealth of 
structural studies have transformed our 
knowledge of Parkin regulation and catalytic 
mechanisms. However, the current picture is 
incomplete, leading to several possible models 
of Parkin catalysis, which has implications for 
understanding how the ARPD-associated mu-
tations affect the protein and thus PD patho-
genesis.  
The major function of Parkin is to ligate 
ubiquitin to lysine residues, an essential post-
translational modification involved in almost 
every cellular pathway. Ubiquitination occurs 
via the sequential action of three enzymes: an 
E1-activating enzyme, an E2-conjugating en-
zyme, and an E3 ligase. Parkin belongs to the 
RBR [RING–in-between-RING (IBR)–RING] fam-
ily of E3 ligases, which contain a RING1 domain 
for E2 recruitment, a catalytic domain (RING2) 
through which transfer of ubiquitin is medi-
ated, and a linking IBR domain (2). There are 14 
RBR family members, including HOIP (HOIL-1–
interacting protein), HHARI (human homolog of 
Ariadne), and Dorfin (double ring-finger). Ow-
ing to its relevance in ARPD, Parkin is the most 
studied RBR ligase and thus also serves as an 
important model for understanding RBR mech-
anism.  
Parkin comprises five domains: ubiquitin-
like domain (Ubl), RING0, RING1, IBR, and 
RING2. The Ubl and RING0 domains are unique 
to Parkin, with the RBR module common to all 
RBR ligases. ARPD-associated PRKN mutations 
are distributed across all five domains and are 
also found within domain-domain interfaces 
and linker regions. This broad distribution of 
mutations across all of Parkin suggests the 
structural integrity of all domains is important 
in ARPD pathogenesis. Parkin adopts an autoin-
hibited conformation mediated by its amino-
terminal Ubl domain (3). The Ubl is joined to 
the carboxyl-terminal RING0-RBR (R0RBR) do-
mains by a flexible 65–amino acid linker. Crystal 
structures of R0RBR Parkin, with both the Ubl 
and linker removed, reveal a rigid core formed 
of RING0, RING1, and RING2 domains, with the 
IBR domain showing degrees of flexibility (4, 5). 
Structures of Parkin that include the Ubl do-
main show that the Ubl is associated with 
RING1 (4, 6, 7). Each structure highlights several 
autoinhibitory features: The RING0 partially oc-
cludes the catalytic cysteine (Cys431); a small 
helical element [repressor element of Parkin 
(REP)] along with the Ubl domain blocks the 
predicted E2 binding site on RING1; and finally, 
the distance between the RING2 Cys431 and 
predicted E2 catalytic cysteine is over 30 Å, 
which is too far to allow transfer of ubiquitin. 
Thus, for full Parkin function, not only are acti-
vators required to disrupt the autoinhibitory 
mechanisms, but large conformational changes 
are predicted to bridge the distance between 
catalytic sites.  
Multiple ARPD-associated proteins such as 
Parkin, PINK1, and DJ-1 (also known as PARK7), 
play roles in mitochondrial homeostasis, sug-
gesting that dysfunction in this process may be 
a feature of ARPD. PINK1 phosphorylates Par-
kin at Ser65 of the Ubl domain, which increases 
its ubiquitin ligase activity (1). In addition to di-
rectly phosphorylating Parkin (pParkin), PINK1 
phosphorylates ubiquitin at the equivalent 
Ser65 (pUb), which leads to activation of Parkin 
(1). Allosteric binding of pUb to Parkin weakens 
Ubl association with the R0RBR domains in 
trans (6-8), and results in straightening of helix 
3 within RING1 to facilitate movement of the 
IBR domain (8, 9). Furthermore, PINK1 phos-
phorylates Parkin-pUb more efficiently than 
Parkin alone, suggesting that displacement of 
the Ubl is required for full kinase activity (10). In 
pParkin, the pUbl is released to form an ex-
tended conformation, and only in the presence 
of pUb (11). Point mutations that disrupt indi-
vidual autoinhibitory features of Parkin show 
that upon activation with pUb, Parkin under-
goes conformational changes that release both 
REP and the Ubl domain (12).  
E2s transfer ubiquitin to Parkin, yet interac-
tion between E2 and autoinhibited Parkin is 
weak (6). However, phosphorylation of Parkin 
and ubiquitin renders the E2 interaction meas-
urable (6, 7). Although the interaction of pPar-
kin-pUb and E2s is low, it is increased when the 
E2 is loaded with ubiquitin (E2~Ub) (7). Finally, 
computational analyses predict that Ubl phos-
phorylation initiates an unwinding of domains 
(13). Thus, the prevailing view of PINK1-
mediated Parkin activation is one where both 
phosphorylation events are needed to drive 
conformational changes to release the Ubl do-
main, the REP, and potentially, the RING0 do-
main to allow binding of E2~Ub and ubiquitin 
transfer. However, the structure of pUb bound 
to the R0RBR domains shows no movement of 
the REP (8). Furthermore, a recent crystal struc-
ture of all five human Parkin domains 
(UblR0RBR) bound to pUb shows no displace-
ment of the Ubl domain or the REP, nor altera-
tion of the catalytic cysteine environment (9). 
One caveat is that the Ubl-RING0 linker is miss-
ing. This linker is not conserved in Parkin 
orthologs, but does influence in vitro activity 
(7). Furthermore, Parkin is not phosphorylated 
in this structure and there is no E2~Ub present. 
The straightening of RING1 helix 3 observed in 
the pUb-R0RBR structure is also observed in 
the presence of the Ubl domain (8, 9). In this 
context, however, the IBR is displaced, reveal-
ing a hidden ubiquitin binding site on RING1 he-
lix 3 that is proposed to interact with the donor 
ubiquitin from E2~Ub. Thus, pUb and ubiquitin 
bind on opposing sides of the now-straight-
ened RING1 helix 3, and mutation of either face 
leads to reduced affinity for pUb as well as 
E2~Ub (13, 14).  
This bipartite binding of ubiquitin mole-
cules is also observed in the crystal structure of 
another RBR ligase, HOIP, where ubiquitin 
binds in the equivalent position as pUb, and 
E2~Ub binding corresponds to the hidden ubiq-
uitin binding site (14). Both of these structures 
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show that the catalytic cysteine and the donor 
ubiquitin are still too far for ubiquitin transfer 
from E2 to Cys431 in cis. Does the E2 to RING2 
transfer of ubiquitin require further conforma-
tional changes of the RBR modules, or are 
other mechanisms possible? This conundrum 
is reminiscent of the allegory of the long 
spoons where in Hell, the inability to feed one-
self with such unwieldly tools is circumvented 
in Heaven by feeding one another. Interest-
ingly, self-association of E3 molecules has been 
reported to support Parkin activity both in vitro 
and in cells (15), thus raising the possibility of 
trans-cooperation for catalytic function (see 
the figure). Further support for this comes 
from the crystal structure of HOIP RBR-E2~Ub 
complex, where the RING2 of a neighboring 
molecule is in proximity to E2~Ub bound to a 
different RBR module (14). This “domain-
swapped” dimer suggests the possibility of a 
trans-based mechanism. Intriguingly HOIP 
functions biologically in concert with another 
RBR ligase, HOIL-1L (heme-oxidized IRP2 ubiq-
uitin ligase 1 homolog), suggesting that other 
RBR ligases may function in collaboration, akin 
to two molecules of Parkin  
Although these recent studies raise the 
possibility of a cooperative model for Parkin 
function, there remain several important cave-
ats. One is that a cooperative model does not 
explain E2 interaction as the REP and Ubl re-
main attached at the E2 binding site. In addi-
tion, the absence of the Ubl-RING0 linker, re-
moved to aid high-resolution crystallography, 
necessarily reduces interdomain flexibility. Fur-
ther, the lack of a structure of pParkin makes it 
challenging to fully understand the role of Par-
kin phosphorylation, as phosphorylation of the 
Ubl and pUb binding releases the Ubl domain 
and greatly enhances E2~Ub interaction. Fi-
nally, Parkin mutants can rescue each other by 
functioning in trans, but does wild-type Parkin 
cooperate for ubiquitin transfer? To distinguish 
these models, rescuing Parkin mutants defi-
cient in one part of the transfer cascade with 
others deficient in another would help deci-
pher at which stage cooperation can occur. 
Currently, the data supporting each model 
do not exclude the other model, and therefore, 
both modes of ubiquitin transfer—through 
conformational change or through cooperative 
binding—could occur. Parkin is mainly cyto-
plasmic, yet PINK1 resides at the mitochondria. 
Does this mean that Parkin is only activated at 
the mitochondria, or are there alternative 
mechanisms dependent on subcellular locali-
zation? For example, ubiquitin-interacting mo-
tifs on Parkin substrates have been shown to 
increase Parkin activity (3). Therefore, Parkin 
may employ distinct mechanisms of activation 
in different cellular contexts, which could in-
clude structural rearrangement and/or cooper-
ation between molecules. Distinguishing be-
tween these models will facilitate 
understanding how and when Parkin recog-
nizes substrates, and how ARPD-associated 
mutations disrupt Parkin function. Understand-
ing Parkin’s catalytic cycle will be important for 
targeting Parkin for therapeutic intervention. It 
will be fascinating to see what further confor-
mations and mechanisms emerge as the un-
derstanding of the catalytic cycle of Parkin-me-
diated ubiquitin transfer deepens.  
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Figure 1 Charging Parkin: Conformational change 
and cooperation models for Parkin function 
For RBR ligases to function, they must engage the 
E2~Ub conjugate and transfer ubiquitin to the cat-
alytic Cys in a transthiolation reaction prior to sub-
strate lysine ubiquitination.   
Models of Ubiquitin transfer to Cys431. 
Model 1: Conformational changes release the REP-
Ubl and the RING2 for E2~Ub binding and exposure 
of Cys431. This conformational change facilitates 
juxtaposition of the catalytic cysteines for trans-
thiolation. Model 2: The REP-Ubl is destabilized 
and the ubiquitin binding site revealed. To bridge 
the distance for ubiquitin transfer to Cys431, Parkin 
cooperates with another E2~Ub bound Parkin 
complex to load its Cys431 residue.  
Ubl, ubiquitin-like domain (green); Ub, ubiquitin 
(purple); R0, RING0 (gray); R1, RING1 (red); R2, 
RING2 (cyan); IBR; in-between-ring domain 
(brown); REP, repressor of Parkin (yellow); pS65, 
phosphorylation of serine 65; PINK1, PTEN-
induced putative kinase 1. 
 
